Medical devices, healthcare technology and the business of care
PMA approval · P240036

OmniaSecure MRI SureScan Lead Model 3930M

Medtronic, Inc. · Decision date Apr 22, 2025

MEDTECHLEDGER EXPLANATIONP240036

What did the FDA approve?

FDA approved PMA P240036 for the OmniaSecure MRI SureScan Lead Model 3930M on April 22, 2025. The applicant is Medtronic, Inc., and the product code is NVY under the permanent defibrillator electrodes category.

The approval statement describes the lead as single use in the right ventricle for pacing, sensing, cardioversion, and defibrillation when a cardiac implantable electronic device is indicated for patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias. It also includes adolescent pediatric patients who are at least 30 kg and at least 12 years of age, and whose cardiac anatomy is conducive to RV coil placement.

The database record does not include a supplement type or supplement reason, so no additional relationship to a prior PMA is established by the supplied fields. The statement reports an intended purpose, not independent proof of safety or clinical effectiveness.

FDA approval order statement

The Model 3930M lead is intended for single use in the right ventricle for pacing, sensing, cardioversion, and defibrillation when a cardiac implantable electronic device is indicated to treat patients who have experienced, or are at significant risk of developing, life-threatening ventricular tachyarrhythmias.This includes adolescent pediatric patients who are at least 30 kg and are also at least 12 years of age, and whose cardiac anatomy is conducive to RV coil placement.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Apr 22, 2025

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P240036
Regulatory pathway
Premarket approval application
Product code
NVY
Decision code
APPR
Decision date
Apr 22, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Permanent defibrillator electrodes.

Product code
NVY
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240036 received

    Application receipt date recorded by FDA.

  2. P240036 · FDA decision

    APPR

  3. P240036/S007 · Related supplement

    OmniaSecure MRI SureScan Lead Model 3930M

Timeline entries are records held by MedtechLedger for P240036. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240036

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
8200 Coral Sea St. N.E, Mounds View, MN, 55112

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records